Gilead Sciences to Acquire Ouro Medicines for $1.675B Upfront and Add Clinical-Stage OM336
Gilead Sciences will pay $1.675 billion upfront plus up to $500 million in milestones to acquire Ouro Medicines and its clinical-stage BCMA×CD3 engager OM336 for autoimmune therapies. OM336 demonstrated efficacy in Phase 1/2 studies for AIHA and ITP and holds Fast Track and Orphan designations, with registrational studies set for 2027.
1. Acquisition Structure
Gilead Sciences entered into a definitive agreement to acquire privately held Ouro Medicines with an upfront cash payment of $1.675 billion and up to $500 million in contingent milestone payments. The deal, which expands Gilead’s inflammation portfolio, remains subject to customary closing conditions.
2. OM336 Clinical Profile
OM336 is a clinical-stage BCMA×CD3 bispecific T cell engager designed to deliver rapid, deep B cell depletion after a limited subcutaneous treatment course. In Phase 1/2 studies targeting autoimmune hemolytic anemia and immune thrombocytopenia, OM336 showed efficacy and a differentiated safety profile and has both Fast Track and Orphan Drug designations.
3. Galapagos Collaboration
Under a planned collaboration, Galapagos would fund OM336 development through registrational studies, retain Ouro employees and co-develop the asset. Gilead would secure worldwide commercialization rights outside Greater China and pay royalties to Galapagos on net sales.